Cover Image
市場調查報告書

骨關節炎:開發平台分析

Osteoarthritis - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 232841
出版日期 內容資訊 英文 270 Pages
訂單完成後即時交付
價格
Back to Top
骨關節炎:開發平台分析 Osteoarthritis - Pipeline Review, H1 2017
出版日期: 2017年03月08日 內容資訊: 英文 270 Pages
簡介

骨關節炎,是最常見的關節炎之一,是指軟骨,保護關節的材料損壞的慢性狀態。這成為骨頭互相摩擦的原因,導致僵硬、疼痛、關節動作低下。危險因子 有高齡,關節受傷,肥胖等。一般的症候,有關節的疼痛和僵硬,動了之後疼痛變得厲害,骨刺,吱嘎作響等。 治療為依據手、手腕、頭、背、膝、腰等損傷的關節狀態,進行藥物療法和運動。

本報告提供骨關節炎的治療藥開發平台的現狀及最新更新的各開發階段比較分析,企業和研究機關開發中的治療藥,治療藥的評估,後期階段及中止的計劃相關資訊等最新的新聞和發表。

簡介

  • 調查範圍
  • 骨關節炎 概要

治療藥的開發

  • 開發中產品;概要
  • 開發中產品;比較分析

企業開發中的治療藥

大學/機關研究中的治療藥

開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

企業開發中的產品

大學/機關研究中的產品

治療藥開發作的企業

  • A. Menarini Industrie Farmaceutiche Riunite Srl
  • AbbVie Inc.
  • Abiogen Pharma S.p.A.
  • Ablynx NV
  • Achelios Therapeutics, Inc.
  • Addex Therapeutics Ltd
  • Akari Therapeutics, Plc
  • Amura Holdings Limited
  • Arcarios BV
  • 旭化成製藥
  • Asklepios BioPharmaceutical, Inc.
  • Astellas Pharma Inc.
  • Asterias Biotherapeutics, Inc.
  • Axsome Therapeutics, Inc.
  • Biopharm GmbH
  • Can-Fite BioPharma Ltd.
  • Cara Therapeutics, Inc.
  • Cardax Pharmaceuticals, Inc.
  • Cellceutix Corporation
  • Cellular Biomedicine Group, Inc.
  • Chong Kun Dang Pharmaceutical Corp.
  • Dong-A ST Co., Ltd.
  • Eli Lilly and Company
  • Evgen Pharma PLC
  • Galapagos NV
  • Genequine Biotherapeutics GmbH
  • GlaxoSmithKline Plc
  • IntelliCell BioSciences Inc.
  • Jeil Pharmaceutical Co., Ltd.
  • Jenrin Discovery, Inc.
  • K-Stemcell Co., Ltd.
  • Levolta Pharmaceuticals, Inc.
  • Medivir AB
  • Merck KGaA
  • Mesoblast Limited
  • Mor Research Application Ltd
  • NicOx S.A.
  • Nordic Bioscience A/S
  • Novartis AG
  • Ocata Therapeutics, Inc.
  • Omeros Corporation
  • 小野藥品工業
  • OrthoCyte Corporation
  • Osteologix Holdings Plc
  • Pfizer Inc.
  • Pharmalink AB
  • PLx Pharma Inc.
  • ProteoThera, Inc.
  • Regeneus Ltd
  • ReqMed Company, Ltd.
  • Sanofi
  • 生化學工業
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
  • STELIS Biopharma Pvt. Ltd.
  • Stempeutics Research Private Limited
  • Symic Biomedical, Inc.
  • 武田藥品工業
  • TissueGene, Inc.
  • Upsher-Smith Laboratories, Inc.
  • Yooyoung Pharmaceutical Co., Ltd.
  • Yuhan Corporation
  • Yungjin Pharm. Co., Ltd.
  • Zimmer Biomet Holdings, Inc.
  • Zynerba Pharmaceuticals, Inc.

治療藥的評估

  • 單劑產品
  • 組合產品
  • 各標的
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • (apocynin + paeonol)
  • (clodronate disodium + hyaluronic acid)
  • ABT-981
  • AlloJoin
  • AM-3701
  • AM-3876
  • Anatabine
  • 骨關節炎抑制劑
  • 骨關節炎 TGF-β1阻礙抗體
  • ARC-118
  • AS-001
  • ASP-7962
  • BNP-OA
  • BRM-421
  • CDX-085
  • celecoxib
  • CHND-1
  • CKD-941
  • clodronate disodium
  • CR-8357
  • CR-845
  • CRB-0017
  • CS-30MS02
  • DA-5202
  • DIS-BIO-EPS
  • DNX-314
  • 骨疾病、骨關節炎治療藥
  • 骨關節炎治療藥
  • 骨關節炎Renin Angiotensin抑制劑
  • 骨關節炎、骨折骨形成蛋白調整藥
  • 免疫學、代謝性疾病、肌肉骨骼障礙的PPAR-δ調整藥
  • duloxetine hydrochloride DR
  • fasitibant chloride
  • GLPG-1972
  • GQ-203
  • GQ-303
  • GSK-2394002
  • GZ-389988
  • JD-4000 Series
  • Kartogenin
  • KBP-056
  • ketoprofen
  • KM-278
  • LEVI-04
  • LH-023
  • LNA-043
  • MIV-711
  • 發炎性疾病、骨關節炎的單株抗體
  • 骨關節炎單株抗體抑制劑
  • MOR-106
  • MSBCAR-001
  • naproxcinod
  • NBS-101
  • NStride APS
  • OAX-1
  • ONO-4474
  • OTXCP-03
  • OTXCP-07
  • pentosan多硫酸鈉
  • 骨關節炎肽
  • piclidenoson
  • PL-1100
  • PRO-1
  • Progenza
  • 骨關節炎蛋白質
  • 骨關節炎、氣喘蛋白質
  • 類風濕性關節炎、骨關節炎蛋白質
  • 肥胖、骨關節炎、腎線維症、亞伯氏症候群 BMP-7活性蛋白質
  • PRX-167700
  • 骨關節炎組換肽
  • 骨關節炎、中樞神經IL-4/IL-10受體活性組換蛋白質
  • 骨關節炎IGF-1受體工作組換蛋白質
  • 骨質疏鬆症、骨關節炎PTH受體工作組換蛋白質
  • ReJoin
  • Salmon Calcitonin
  • SAR-396049
  • SB-061
  • SBL-005
  • SI-613
  • SM-04690
  • 變性性關節炎小分子
  • 骨關節炎小分子
  • 適合免疫學、血液學、神經疾病A2A促效劑
  • 骨關節炎MMP13抑制劑
  • 焦慮症、循環系統疾病、骨關節炎GPR22標靶藥物
  • 免疫學、代謝障礙、肌肉骨骼障礙小分子
  • 免疫學、肌肉骨骼障礙、代謝障礙小分子
  • 骨關節炎小分子
  • 免疫學、腸胃障礙、神經學、血液疾病TNFR1拮抗劑
  • 骨關節炎ADAMTS-5抑制劑
  • 骨關節炎補體系蛋白質抑制劑
  • 骨關節炎、骨質疏鬆症激化酵素抑制劑
  • 骨關節炎MMP-13抑制劑
  • sprifermin
  • 自體免疫疾病幹細胞療法
  • 中樞神經、CVS、皮膚疾病、免疫疾病n、代謝障礙幹細胞療法
  • 變性性關節炎幹細胞療法
  • 膝關節炎幹細胞療法
  • 多發性硬化症、類風濕性關節炎、骨關節炎、自閉症、肺支氣管發育不良、心臟衰竭、腦損傷性麻痺幹細胞療法
  • 骨關節炎幹細胞療法
  • 骨關節炎、真性糖尿病、急性肝功能衰竭心肺功能甦醒後疾病、神經退行性疾病幹細胞療法
  • Stempeucel
  • 關節炎基質細胞療法
  • Sulforadex
  • tonogenchoncel-L
  • TPX-100
  • TRBN-0224
  • UGP-302
  • VOLT-01
  • X-0002
  • XT-101
  • XT-150
  • YH-14619
  • YRA-1909
  • YY-1201
  • zoledronic acid
  • ZYN-002
  • ■最近的開發平台趨勢

暫停中的計劃

開發中止的產品

產品開發里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9151IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Osteoarthritis - Pipeline Review, H1 2017, provides an overview of the Osteoarthritis (Immunology) pipeline landscape.

Osteoarthritis (OA) is one of the most common forms of arthritis. It is a chronic condition in which the cartilage breaks down. Symptoms of osteoarthritis include sore or stiff joints, pain that is worse after activity, bone spurs and grating sensation. Risk factors include older age, joint injuries and obesity. Treatment includes surgery, medications like non-steroidal anti-inflammatory drugs (NSAIDs) and exercise.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Osteoarthritis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Osteoarthritis (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Osteoarthritis (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Osteoarthritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 7, 21, 14, 46 and 14 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 5 and 5 molecules, respectively.

Osteoarthritis (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Osteoarthritis (Immunology).
  • The pipeline guide reviews pipeline therapeutics for Osteoarthritis (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Osteoarthritis (Immunology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Osteoarthritis (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Osteoarthritis (Immunology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Osteoarthritis (Immunology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Osteoarthritis (Immunology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Osteoarthritis - Overview
  • Osteoarthritis - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Osteoarthritis - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Osteoarthritis - Companies Involved in Therapeutics Development
    • A. Menarini Industrie Farmaceutiche Riunite Srl
    • AbbVie Inc
    • Abiogen Pharma SpA
    • Ablynx NV
    • Achelios Therapeutics Inc
    • Addex Therapeutics Ltd
    • Amgen Inc
    • Amura Holdings Ltd
    • Arcarios BV
    • Asahi Kasei Pharma Corp
    • Asklepios BioPharmaceutical Inc
    • Astellas Pharma Inc
    • Biopharm GmbH
    • Bone Therapeutics SA
    • Can-Fite BioPharma Ltd
    • Cardax Inc
    • Cellular Biomedicine Group Inc
    • Cipla Ltd
    • Corestem Inc
    • Dong-A Socio Holdings Co Ltd
    • Evgen Pharma Plc
    • F. Hoffmann-La Roche Ltd
    • Galapagos NV
    • Gemphire Therapeutics Inc
    • GeneFrontier Corp
    • Genequine Biotherapeutics GmbH
    • GlaxoSmithKline Plc
    • HSRx Group
    • InKemia IUCT Group SA
    • International Stem Cell Corp
    • Jeil Pharmaceutical Co Ltd
    • Jenrin Discovery Inc
    • K-Stemcell Co Ltd
    • Kang Stem Biotech Co Ltd
    • Levolta Pharmaceuticals Inc
    • LG Chem, Ltd.
    • Marina Biotech Inc
    • Medivir AB
    • Merck KGaA
    • Mesoblast Ltd
    • Mor Research Application Ltd
    • NicOx SA
    • Nordic Bioscience A/S
    • Novartis AG
    • NovelMed Therapeutics Inc
    • Omeros Corp
    • Ono Pharmaceutical Co Ltd
    • OrthoCyte Corp
    • Osteologix Holdings Plc
    • Pfizer Inc
    • Pharmalink AB
    • Philogen SpA
    • PhytoHealth Corp
    • PLx Pharma Inc
    • ProteoThera Inc
    • Regeneus Ltd
    • Regulaxis SAS
    • Rottapharm Biotech Srl
    • Samumed LLC
    • Seikagaku Corp
    • Stelis Biopharma Pvt Ltd
    • Takeda Pharmaceutical Company Ltd
    • TissueGene Inc
    • Yooyoung Pharmaceutical Co Ltd
    • Yuhan Corp
    • Yungjin Pharm Co Ltd
    • Zimmer Biomet Holdings Inc
  • Osteoarthritis - Drug Profiles
    • (clodronate disodium + hyaluronic acid) - Drug Profile
    • (methylprednisolone + zoledronic acid) - Drug Profile
    • 4-P004 - Drug Profile
    • ABT-981 - Drug Profile
    • ALLO-ASC - Drug Profile
    • AlloJoin - Drug Profile
    • AM-3701 - Drug Profile
    • AM-3876 - Drug Profile
    • Anatabine - Drug Profile
    • Antibody for Osteoarthritis - Drug Profile
    • Antibody to Inhibit TGF-Beta 1 for Osteoarthritis - Drug Profile
    • apocynin + paeonol - Drug Profile
    • ARC-118 - Drug Profile
    • AS-001 - Drug Profile
    • BNP-OA - Drug Profile
    • CDX-085 - Drug Profile
    • celecoxib - Drug Profile
    • Cell Therapy for Osteoarthritis - Drug Profile
    • Chondrostem - Drug Profile
    • clodronate disodium - Drug Profile
    • CMX-020 - Drug Profile
    • CR-8357 - Drug Profile
    • CRB-0017 - Drug Profile
    • CS-30MS02 - Drug Profile
    • DA-5202 - Drug Profile
    • denosumab - Drug Profile
    • DIS-BIO-EPS - Drug Profile
    • DNX-314 - Drug Profile
    • Drug for Bone Diseases and Osteoarthritis - Drug Profile
    • Drug for Osteoarthritis - Drug Profile
    • Drug for Osteoarthritis - Drug Profile
    • Drugs to Modulate Bone Morphogenetic Protein for Osteoarthritis and Fracture - Drug Profile
    • Drugs to Modulate PPAR-Delta for Metabolic and Musculoskeletal Disorders - Drug Profile
    • fasitibant chloride - Drug Profile
    • gemcabene calcium - Drug Profile
    • GFC-301 - Drug Profile
    • GLPG-1972 - Drug Profile
    • GQ-203 - Drug Profile
    • GQ-303 - Drug Profile
    • GSK-2394002 - Drug Profile
    • JD-4000 Series - Drug Profile
    • Jointstem - Drug Profile
    • JTA-004 - Drug Profile
    • Kartogenin - Drug Profile
    • KBP-056 - Drug Profile
    • ketoprofen - Drug Profile
    • LEVI-04 - Drug Profile
    • LH-021 - Drug Profile
    • LNA-043 - Drug Profile
    • MIV-711 - Drug Profile
    • Monoclonal Antibodies for Oncology, Inflammation and Osteoarthritis - Drug Profile
    • Monoclonal Antibody Conjugates for Osteoarthritis - Drug Profile
    • Monoclonal Antibody for Osteoarthritis - Drug Profile
    • MPC-75IA - Drug Profile
    • naproxcinod - Drug Profile
    • NBS-101 - Drug Profile
    • NStride APS - Drug Profile
    • ONO-4474 - Drug Profile
    • OTXCP-03 - Drug Profile
    • OTXCP-07 - Drug Profile
    • PF-152 - Drug Profile
    • PHDC-02 - Drug Profile
    • piclidenoson - Drug Profile
    • PL-1100 - Drug Profile
    • PN-6047 - Drug Profile
    • PRO-1 - Drug Profile
    • Progenza - Drug Profile
    • Protein for Osteoarthritis and Asthma - Drug Profile
    • Proteins for Rheumatoid Arthritis and Osteoarthritis - Drug Profile
    • PRX-167700 - Drug Profile
    • Recombinant Protein for Osteoarthritis - Drug Profile
    • Recombinant Protein to Agonize ALK and BMP Receptors for Alport Syndrome, Kidney Diseases, Metabolic Disorders and Osteoarthritis - Drug Profile
    • Recombinant Protein to Agonize IGF-1 Receptor for Osteoarthritis - Drug Profile
    • Recombinant Protein to Agonize IL-4 and IL-10 Receptors for Osteoarthritis and CNS - Drug Profile
    • Reg-O3 - Drug Profile
    • ReJoin - Drug Profile
    • salmon calcitonin - Drug Profile
    • SBL-005 - Drug Profile
    • SFX-01 - Drug Profile
    • SI-613 - Drug Profile
    • SM-04690 - Drug Profile
    • Small Molecule for Degenerative Arthritis - Drug Profile
    • Small Molecule for Osteoarthritis - Drug Profile
    • Small Molecule for Osteoarthritis - Drug Profile
    • Small Molecule for Osteoarthritis - Drug Profile
    • Small Molecule to Agonize A2A for Immunology, Hematological and Neurological Disorders - Drug Profile
    • Small Molecule to Target GPR22 for Anxiety, Cardiovascular Diseases and Osteoarthritis - Drug Profile
    • Small Molecules for Metabolic and Musculoskeletal Disorders - Drug Profile
    • Small Molecules for Musculoskeletal and Metabolic Disorders - Drug Profile
    • Small Molecules for Osteoarthritis - Drug Profile
    • Small Molecules for Osteoarthritis - Drug Profile
    • Small Molecules to Inhibit ADAMTS-5 for Osteoarthritis - Drug Profile
    • Small Molecules to Inhibit iNOS for Osteoarthritis - Drug Profile
    • Small Molecules to Inhibit MMP-13 for Osteoarthritis - Drug Profile
    • sprifermin - Drug Profile
    • Stem Cell Therapy for Articular Cartilage Lesions and Osteoarthritis - Drug Profile
    • Stem Cell Therapy for Autoimmune Diseases - Drug Profile
    • Stem Cell Therapy for CNS Disorders, Rheumatoid Arthritis, Osteoarthritis, Bronchopulmonary Dysplasia and Heart Failure - Drug Profile
    • Stem Cell Therapy for Diabetes Mellitus, Acute Liver Failure, Osteoarthritis and Neurodegenerative Diseases - Drug Profile
    • Stem Cell Therapy for Osteoarthritis and Rheumatoid Arthritis - Drug Profile
    • Stem Cell Therapy for Osteoarthritis, Atherosclerosis and Arteriosclerosis Obliterans - Drug Profile
    • Stempeucel - Drug Profile
    • tonogenchoncel-L - Drug Profile
    • TPX-100 - Drug Profile
    • TRBN-0224 - Drug Profile
    • UGP-302 - Drug Profile
    • VA-694 - Drug Profile
    • X-0002 - Drug Profile
    • XT-101 - Drug Profile
    • XT-150 - Drug Profile
    • YH-14619 - Drug Profile
    • YRA-1909 - Drug Profile
    • YY-1201 - Drug Profile
    • YYD-302 - Drug Profile
  • Osteoarthritis - Dormant Projects
  • Osteoarthritis - Discontinued Products
  • Osteoarthritis - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Osteoarthritis, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..3), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..4), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..5), H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Osteoarthritis - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H1 2017
  • Osteoarthritis - Pipeline by AbbVie Inc, H1 2017
  • Osteoarthritis - Pipeline by Abiogen Pharma SpA, H1 2017
  • Osteoarthritis - Pipeline by Ablynx NV, H1 2017
  • Osteoarthritis - Pipeline by Achelios Therapeutics Inc, H1 2017
  • Osteoarthritis - Pipeline by Addex Therapeutics Ltd, H1 2017
  • Osteoarthritis - Pipeline by Amgen Inc, H1 2017
  • Osteoarthritis - Pipeline by Amura Holdings Ltd, H1 2017
  • Osteoarthritis - Pipeline by Arcarios BV, H1 2017
  • Osteoarthritis - Pipeline by Asahi Kasei Pharma Corp, H1 2017
  • Osteoarthritis - Pipeline by Asklepios BioPharmaceutical Inc, H1 2017
  • Osteoarthritis - Pipeline by Astellas Pharma Inc, H1 2017
  • Osteoarthritis - Pipeline by Biopharm GmbH, H1 2017
  • Osteoarthritis - Pipeline by Bone Therapeutics SA, H1 2017
  • Osteoarthritis - Pipeline by Can-Fite BioPharma Ltd, H1 2017
  • Osteoarthritis - Pipeline by Cardax Inc, H1 2017
  • Osteoarthritis - Pipeline by Cellular Biomedicine Group Inc, H1 2017
  • Osteoarthritis - Pipeline by Cipla Ltd, H1 2017
  • Osteoarthritis - Pipeline by Corestem Inc, H1 2017
  • Osteoarthritis - Pipeline by Dong-A Socio Holdings Co Ltd, H1 2017
  • Osteoarthritis - Pipeline by Evgen Pharma Plc, H1 2017
  • Osteoarthritis - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
  • Osteoarthritis - Pipeline by Galapagos NV, H1 2017
  • Osteoarthritis - Pipeline by Gemphire Therapeutics Inc, H1 2017
  • Osteoarthritis - Pipeline by GeneFrontier Corp, H1 2017
  • Osteoarthritis - Pipeline by Genequine Biotherapeutics GmbH, H1 2017
  • Osteoarthritis - Pipeline by GlaxoSmithKline Plc, H1 2017
  • Osteoarthritis - Pipeline by HSRx Group, H1 2017
  • Osteoarthritis - Pipeline by InKemia IUCT Group SA, H1 2017
  • Osteoarthritis - Pipeline by International Stem Cell Corp, H1 2017
  • Osteoarthritis - Pipeline by Jeil Pharmaceutical Co Ltd, H1 2017
  • Osteoarthritis - Pipeline by Jenrin Discovery Inc, H1 2017
  • Osteoarthritis - Pipeline by K-Stemcell Co Ltd, H1 2017
  • Osteoarthritis - Pipeline by Kang Stem Biotech Co Ltd, H1 2017
  • Osteoarthritis - Pipeline by Levolta Pharmaceuticals Inc, H1 2017
  • Osteoarthritis - Pipeline by LG Chem, Ltd., H1 2017
  • Osteoarthritis - Pipeline by Marina Biotech Inc, H1 2017
  • Osteoarthritis - Pipeline by Medivir AB, H1 2017
  • Osteoarthritis - Pipeline by Merck KGaA, H1 2017
  • Osteoarthritis - Pipeline by Mesoblast Ltd, H1 2017
  • Osteoarthritis - Pipeline by Mor Research Application Ltd, H1 2017
  • Osteoarthritis - Pipeline by NicOx SA, H1 2017
  • Osteoarthritis - Pipeline by Nordic Bioscience A/S, H1 2017
  • Osteoarthritis - Pipeline by Novartis AG, H1 2017
  • Osteoarthritis - Pipeline by NovelMed Therapeutics Inc, H1 2017
  • Osteoarthritis - Pipeline by Omeros Corp, H1 2017
  • Osteoarthritis - Pipeline by Ono Pharmaceutical Co Ltd, H1 2017
  • Osteoarthritis - Pipeline by OrthoCyte Corp, H1 2017
  • Osteoarthritis - Pipeline by Osteologix Holdings Plc, H1 2017
  • Osteoarthritis - Pipeline by Pfizer Inc, H1 2017
  • Osteoarthritis - Pipeline by Pharmalink AB, H1 2017
  • Osteoarthritis - Pipeline by Philogen SpA, H1 2017
  • Osteoarthritis - Pipeline by PhytoHealth Corp, H1 2017
  • Osteoarthritis - Pipeline by PLx Pharma Inc, H1 2017
  • Osteoarthritis - Pipeline by ProteoThera Inc, H1 2017
  • Osteoarthritis - Pipeline by Regeneus Ltd, H1 2017
  • Osteoarthritis - Pipeline by Regulaxis SAS, H1 2017
  • Osteoarthritis - Pipeline by Rottapharm Biotech Srl, H1 2017
  • Osteoarthritis - Pipeline by Samumed LLC, H1 2017
  • Osteoarthritis - Pipeline by Seikagaku Corp, H1 2017
  • Osteoarthritis - Pipeline by Stelis Biopharma Pvt Ltd, H1 2017
  • Osteoarthritis - Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017
  • Osteoarthritis - Pipeline by TissueGene Inc, H1 2017
  • Osteoarthritis - Pipeline by Yooyoung Pharmaceutical Co Ltd, H1 2017
  • Osteoarthritis - Pipeline by Yuhan Corp, H1 2017
  • Osteoarthritis - Pipeline by Yungjin Pharm Co Ltd, H1 2017
  • Osteoarthritis - Pipeline by Zimmer Biomet Holdings Inc, H1 2017
  • Osteoarthritis - Dormant Projects, H1 2017
  • Osteoarthritis - Dormant Projects, H1 2017 (Contd..1), H1 2017
  • Osteoarthritis - Dormant Projects, H1 2017 (Contd..2), H1 2017
  • Osteoarthritis - Dormant Projects, H1 2017 (Contd..3), H1 2017
  • Osteoarthritis - Dormant Projects, H1 2017 (Contd..4), H1 2017
  • Osteoarthritis - Dormant Projects, H1 2017 (Contd..5), H1 2017
  • Osteoarthritis - Discontinued Products, H1 2017
  • Osteoarthritis - Discontinued Products, H1 2017 (Contd..1), H1 2017

List of Figures

  • Number of Products under Development for Osteoarthritis, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Top 10 Molecule Types, H1 2017
  • Number of Products by Stage and Top 10 Molecule Types, H1 2017
Back to Top